Market Rally Extends to Biotech
HENDERSON, NV / ACCESSWIRE / January 9, 2019 / Markets are rallying in first full market week of 2019 and the biotech sector is responding as many oversold small caps are starting to rebound. We've found several that look poised for recovery in the near term.
One that's starting to rebound, Delcath Systems, Inc. (DCTH), has an impressive liver cancer treatments in late-stage development, is already in Phase 3 clinical trials, increased their revenue this past year, and just signed a licensing deal with a projected value of up to $45 million. The stock is still a relative unknown, but the street may be catching on. It's early in the rally, so do your due diligence on DCTH today.
Today we are highlighting: Delcath Systems, Inc. (DCTH), Axsome Therapeutics, Inc. (AXSM), BioPharmX Corporation (NYSE American: BPMX), Axovant Sciences Ltd. (AXON), and Geron Corporation (GERN).
An interventional oncology company focused on treating liver cancers with significant upside potential, Delcath Systems, Inc. (DCTH) (Market Cap: $2.972M, Share Price: $0.3050) ended 2018 with significant news.
The company made major news when it announced a new licensing agreement for CHEMOSAT® commercialization in Europe with medac Gesellschaft für klinische Spezialpräparate mbH (medac). The agreement has a projected value of up to $45 million over the first seven-year term and includes an optional five-year extension. medac is a privately held, multi-national pharmaceutical company based in Hamburg area, Germany. Founded in 1970, medac specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases. The company has offices globally, worldwide partner agreements in over 90 countries, and approximately 1,200 employees.
The medac licensing agreement comes in addition to an announcement about the independent Data Safety Monitoring Board (DSMB) of the Registration trial for Patients with Hepatic Dominant Ocular Melanoma (The FOCUS Trial) completed another pre-specified review (the fourth) of safety data for treated patients in the trial. This review was conducted on data collected from both the prior randomized protocol and the amended single-arm protocol for the FOCUS Trial. The DSMB again recommended continuation of the study without modification.
Also in 2018, Delcath amended their Phase 3 clinical trial, raised $7 million via a rights offering, increased revenue 20% Y/Y, and had data published in European Radiology among several other milestones.
____
Axsome Therapeutics, Inc. (AXSM)(Market Cap: $264.741M, Share Price: $8.88) shot up 164% in very active premarket trade Monday, after announcing a phase 2 trial of its AXS-05 met its primary endpoint, and "significantly improved symptoms of depression."
____
BioPharmX Corporation (NYSE American: BPMX)(Market Cap: $30.411M, Share Price: $0.1429) received a notice of non-compliance from the NYSE in December. After slumping on the news, the stock has started to rebound.
____
Axovant Sciences Ltd. (AXON) (Market Cap: $162.827M, Share Price: $1.07) will be presenting at the 37th Annual J.P. Morgan Healthcare Conference. Pavan Cheruvu, M.D., chief executive officer, will present at 8:00 a.m. PST on Thursday, January 10th, 2019.
____
Geron Corporation (GERN) (Market Cap: $214.3M, Share Price: $1.15) announced that results from IMbark, a Phase 2 clinical trial of imetelstat treatment in Intermediate-2 or High-risk myelofibrosis (MF) patients who are relapsed or refractory to a Janus Kinase (JAK) inhibitor, were presented at the 60th American Society of Hematology (ASH) Annual Meeting in San Diego, California. The oral presentation was made on December 3, 2018 by John Mascarenhas, M.D., Associate Professor of Medicine in the Myeloproliferative Disorders Program of the Tisch Cancer Institute, Division of Hematology/Oncology at the Icahn School of Medicine at Mount Sinai, and an IMbark clinical investigator.
Legal Disclaimer:
This article was written by Regal Consulting, LLC (''Regal Consulting''). Regal Consulting has agreed to a twelve-month term consulting agreement with DCTH dated 8/31/18. The agreement calls for $40,000 in cash, and 15,000 restricted 144 shares of DCTH per month. Issuer agreed to increase monthly cash payment in September to $120,000. All payments were made directly by Delcath Systems, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspecultors.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. DCTH was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.
http://www.regalconsultingllc.com/full legal disclaimer/
Microspeculators.com Full Legal Disclaimer Click Here.
Contact Information:
Company Name: Microcap Speculators
Contact Person: Media Manager
Email: info@microcapspeculators.com
Phone: 1-702-720-6310
Country: United States
Website: http://microcapspeculators.com/
SOURCE: ACR Communications LLC
